跳至主要内容
临床试验/TCTR20220207006
TCTR20220207006已完成不适用

Incidence, Risk Factors and Ophthalmic Clinical Characteristic of Ethambutol-induced Optic Neuropathy: 7-year Experience in Rajavithi Hospital, Thailand.

Rajavithi Hospital0 个研究点目标入组 20 人开始时间: 2022年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20

研究概览

简要总结

The incidence of EON in patients treated with Ethambutol was 0.5%. Age, hypertension, smoking, and duration of ethambutol prescription were risk factors for EON. Some intriguing ophthalmic studies showed loss of retinal nerve fibers, which was more noticeable in the ganglion cell layer.

研究设计

研究类型
Observational

入排标准

年龄范围
N/A (No limit) 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. The patients who received ethambutol for TB treatment at Rajavithi Hospital, Bangkok, Thailand from January 2012 to August 2019.
  • 2. The patients who had decreased vision after ethambutol treatment and were diagnosed as ethambutol-induced optic neuropathy (EON) by experienced neuro-ophthalmologists were included as EON group.
  • 3. The patients who received ethambutol during the study period without visual symptoms were included as Control group.

排除标准

  • 1. EON patients with other ophthalmic conditions resulting in significant visual obscuration such as retinal and macular diseases, cataract, diabetic retinopathy, glaucoma, or other optic neuropathies were excluded.
  • 2. The patients who had incomplete or lost medical record.

研究者

相似试验

Incidence, Risk Factors and Ophthalmic Clinical... | 临床试验